Fresenius Kabi
Products for chronically and critically ill patients
Fresenius Helios
Europe’s leading private healthcare provider
Archive "Stories"
Contact
Nick Stone Senior Vice President Investor Relations Head of Investor Relations
ir-fre@fresenius.com
Dennis Hofmann Head of Corporate Communications T +49 (0) 6172 608-96008
pr-fre@fresenius.com
Share
Facebook
Twitter
LinkedIn
Xing
E-Mail
Services
Print
RSS
December 5, 2016
Tigecycline, an antibiotic, expands Fresenius Kabi's anti-infective portfolio.
